PPTA Europe

PPTA unites companies from around the world and across the plasma therapeutics sector. All working towards a future where every patient has uninterrupted access to life-saving plasma-derived medicinal products (PDMPs). Our industry is committed to scientific excellence, creating hundreds of thousands of jobs, and advancing global health through the groundbreaking work of leading scientists. With supportive policies and better regulatory frameworks, we can reach even more patients worldwide.  ➡ https://lnkd.in/e2Tx7SWD #Foreverypatient #everyday #EUNeedsMorePlasma #PlasmaDonorsSaveLives

⚡Plasma 101: Why is the clinical need for plasma-derived medicines increasing worldwide? Let's break down some of the factors.    1. Increased precision of medical diagnostics.  2. More people are being identified with rare conditions.   3. Emerging clinical evidence show the benefits of PDMPs.  4. Greater awareness helps early diagnosis of rare conditions.  5. Patients live longer and healthier lives than ever before.  6. Medical research finds new applications for PDMPs    To keep up with the growing clinical need for plasma-derived medicines, EU countries should consider adopting best practices from Austria, Czechia, Germany, and Hungary. These countries have shown how the public-private coexistence model can work to boost plasma availability for producing plasma-derived medicines.     It’s a proven approach that could really benefit us all!    #EUNeedsMorePlasma   #TheWorldNeedsMorePlasma  

Plasma donation centers often become community hubs where donors form meaningful connections and friendships with fellow donors and staff who support them. These donor communities create a sense of belonging and shared purpose. Nurturing these donor communities is essential, as they are the backbone that sustains the availability of plasma-derived medicines.  Have you recently visited a plasma collection centre? Share your experience below!👇 

Have you heard of the term ‘diagnostic odyssey’? It is a tough journey many people with rare diseases go through to get a correct diagnosis. During this time, patients frequently experience uncertainty about their health and future. Let's share our thoughts on what makes this process so challenging. What do you think are the biggest obstacles in the diagnostic odyssey? Share in the comments 👇 https://lnkd.in/eH2pqXjt  #rarediseases #together4rare

We have had an incredible year with Nour Abdallah-Khodja as our intern. We hope you gained valuable insights during your time here and will continue to emphasise the importance of patient access to plasma-derived medicines. Thank you for your hard work and the positive impact you've made. Wishing you all the best in your future endeavors! EPSA - European Pharmaceutical Students' Association

At Kedrion, we understand the urgent need to help patients with unmet medical needs. That’s why we are committed to discovering new therapies and producing crucial, life-saving treatments. In 2023, we increased our research and development efforts and expanded our capabilities to support even more people battling rare and ultra-rare conditions. 🔎Dive into our digital Annual Report to see how we did it: https://lnkd.in/dP8JnpX5 #WeAreKedrion #TogetherWeGrow #AnnualReport #GlobalHealthcare

📢 Important Update: On July 17, 2024, the new EU rules on substances of human origin (#SoHORegulation) was published in the Official Journal of the EU. This regulation was adopted by the Council on May 27, 2024, and received approval from the European Parliament on April 24, 2024. Find all the details here: https://lnkd.in/gweNMdiX 

How are plasma availability and accessibility to plasma-derived medicines connected? — >𝐀𝐯𝐚𝐢𝐥𝐚𝐛𝐢𝐥𝐢𝐭𝐲 Plasma availability refers to the global supply of plasma, which is used as the starting material for making plasma-derived medicines. — >𝐀𝐜𝐜𝐞𝐬𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐲 Access to plasma-derived medicines refers to how patients can get these critical medicines. Factors influencing access include policies on pricing, procurement, reimbursement, and more. European patients depend on these life-saving medicines being both available and accessible. This connection is only as strong as its weakest link. Any shortcomings in plasma availability or access policies can affect patient care. Addressing these issues lies at the heart of PPTA's mission and its members' commitment to improving patient access to PDMPs. #EUNeedsMorePlasma #CriticalMedicines #AccessToMedicines

“What we do here is wonderful, cutting-edge scientific stuff. But it’s not just what we do that’s so rewarding, it’s why we do it." - Thomas R. Kreil #drivenbyscience 👇